Ascites is the accumulation of fluid in the spaces between the abdomen and abdominal organs. It is the most common complication associated with cirrhosis, and its development is also a sign of significant portal hypertension. Other conditions that can cause ascites include hepatitis B, hepatitis C, congestive heart failure, kidney disease, and malignancy
Increasing prevalence of cirrhosis, favorable reimbursement scenario, rising occurrence of cancer, development of new drugs, and technological improvements are the key factors driving the ascites market.
However, complications associated with ascites treatment may hinder the growth of the market to an extent. Various complications have been observed with ascites treatment approaches such as bleeding, small bowel perforation, stent placement complications, post-procedural complexities, and others. Some of these complications are rare and life-threatening
The global ascites market is expected to grow at a CAGR of 4.0% during the forecast period 2017-2023.
Taste the market data and market information presented through more than 296 market data tables and figures spread over 251 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “ascites market research report–Global forecast till 2023.”
Get a sample report at https://www.marketresearchfuture.com/sample_request/1909 .
Key Players in the Ascites Market
Some of key the players in the ascites market are Sequana Medical, BioVie, PharmaCyte Biotech Inc., Fresenius SE & Co. KGaA, BD, GI Supply, Medtronic plc, and others.
The Americas dominate the ascites market owing to the well-developed technology, high healthcare expenditure, rising prevalence of cirrhosis, and the presence of the leading players. According to the data suggested by the Centres for Disease Control and Prevention in 2015, around 1.6 % adults have been diagnosed with the chronic liver disease in the U.S. i.e. 3.9 million. It is also stated that from 2000 to 2015 death rates due to the chronic liver disease and cirrhosis increased by 31% in the United States among individuals aged 45–64 years.
Europe holds the second position in the ascites market. It is expected that the support provided by the government bodies for research & development and the increase in a number of surgeries drives the market in European region. The liver is also very prevalent in European region. Owing to the increasing alcohol consumption and obesity, liver cirrhosis is the third most common cause of premature mortality in the UK as compared to other countries in Western Europe, suggested by a study published in BMJ Open in 2017
Asia Pacific region is projected to be the fastest growing region during the forecast period. Rapidly improving technology and the presence of huge patient pool is driving the growth of the market in this region.
The Middle East and Africa hold the least share of the ascites market owing to the presence of poor and slow developing countries, especially, in African region.
Ascites is an abnormal accumulation of fluid in the abdominal cavity. Liver cirrhosis is the most common case of ascites. Its presence is a sign of significant portal hypertension. Other less common factors that may contribute to ascites development are heart failure, kidney failure, cancers, and infection in the pancreas. Malignant ascites has a characteristic role in the progression of ovarian cancer. Malignancy-related ascites have also been observed in malignancies of breast, lung, pancreas, gastric, and liver. Ascites can be detected by physical examination at a volume greater than 1.5 ascites. For a smaller amount of fluid, ultrasound and CT scan are preferred.
Notably, rising prevalence of cirrhosis is the key factors driving the ascites market. As per the study published in Hepatology journal in 2016, it is found that prevalence of the chronic liver disease is higher among Japanese Americans i.e. 6.9%. It is also stated that in whites, alcoholic liver disease was observed as the most common cause of cirrhosis i.e. 38.2%, whereas hepatitis C virus was most common in African Americans i.e. 29.8%
Browse Complete Report at https://www.marketresearchfuture.com/reports/ascites-market-1909 .
The global ascites market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the market is classified into transudative ascites, and exudate ascites.
On the basis of the diagnosis, the market is segmented into ultrasound, CT scan, laparoscopy, angiography, and others.
On the basis of the treatment, the market is segmented into surgeries and others. The surgeries segment is further segmented into peritoneovenous shunting, liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), and other surgeries.
On the basis of the end -users, the market is segmented into hospital, and clinics, ambulatory surgical centers, diagnostic centers, and others.
- The global ascites market is expected to reach USD 3710.4 million by 2023 at a CAGR of 4.0%.
- On the basis of the diagnosis, the ultrasound segment is expected to command the largest market share of 9% over the review period and it is also expected to grow at the fastest CAGR of 4.4% during the forecast period 2017-2023
- On the basis of the type, exudate ascites is expected to command the largest market share of 55.8% over the review period and it is also expected to grow at the fastest CAGR of 4.4% during the forecast period 2017-2023
- The Americas hold the largest share of the global ascites market and is expected to reach USD 1,292.2 million by 2023
- Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 4.5% over the 2017-2023
More Inquire at https://www.marketresearchfuture.com/enquiry/1909 .
The Americas dominate the ascites market owing to the well-developed technology, high healthcare expenditure, rising prevalence of cirrhosis, and the presence of the leading players in the region. According to the data suggested by the Centers for Disease Control and Prevention in 2015, around 1.6 % adults have been diagnosed with the chronic liver disease in the United States i.e. 3.9 million. It is also stated that from 2000 to 2015 death rates due to the chronic liver disease and cirrhosis was increased by 31% in the United States among individuals aged 45–64 years.
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –